ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).
This multicenter, randomized, double-blind study included 152 participant with hypertriglyceridemia (triglycerides > 150mg/dL) and established or increased risk of ASCVD. The study involved an 8-week screening period, a 23-week treatment period and a 13-week follow-up period. Patients were randomized 1:1 to recieve either olezarsen adminstered by injection once every 4 weeks, or placebo.
Findings suggest that in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, 50mg or 80mg olezarsen monthly significantly reduced triglyceride levels, as well as meaningful reductions in apolipoprotein B and non-high-density lipoprotein cholesterol, both of which are markers of atherogenic risk.
Interview Questions:
- What is the reasoning behind this study?
- Could you tell us the mechanism of action of olezarsen
- What was the patient population and study design?
- What are the key findings?
- What are the implications of these findings on clinical practice?
- Where are the knowledge gaps?
- What are the next steps?
Recorded onsite at the ACC Conference in Atlanta, 2024.
For more content from ACC.24 head to the Late-breaking Science Video Collection.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Editors: Jordan Rance, Mirjam Boros
Video Specialists: Dan Brent, Tom Green, Mike Knight
Comments